What is SRPT's P/E ratio?

SAREPTA THERAPEUTICS INC (SRPT) currently trades at a P/E ratio of 3.34.

SAREPTA THERAPEUTICS INC reports a Return on Equity (ROE) of 4.32%.

What is SRPT's dividend yield?

SAREPTA THERAPEUTICS INC offers a dividend yield of 0.00%.

What is SRPT's Deepscope Quality Score?

Deepscope rates SRPT's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy SRPT?

Deepscope's AI Timing Score for SRPT is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does SRPT belong to?

SAREPTA THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.

SRPT (NASDAQ) 株価分析 | SAREPTA THERAPEUTICS INC

Stock Check Daily update data at 9:30 AM
(Price: 2026-06-05 | FS: 2026-03-31)

SRPT

SAREPTA THERAPEUTICS INC

US:NASDAQ STOCK Healthcare >> Biotechnology News 89

USD 15.75

-0.91 (-5.46%) Day Change

Watchlist Portfolio Compare Chart

3.34

P/E

0.56

D/E

4.3%

ROE

2.1%

ROA

0.00%

Div Yield

-0.02

PEG

SAREPTA THERAPEUTICS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 15.75 Price -0.91 (-5.46%) Day Change	NEWS SCORE: 89

SRPT, ファンダメンタルスコアはnot good ( ファンダメンタル = 23) そしてテクニカルスコアは ...(Sign In to See)...

Loading chart...

23 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROEが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
NPMの伸びが低い

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Lorem ipsum dolor sit amet

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...

Deepscope 分析

45%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	89
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	15.75
PBV / Sector	1.17 / 4.63 GREAT
Earning Per Share	0.58

PE / Sector	3.34 / 17.43 GREAT
PEG or PE/Growth / Sector	-0.02 / 0.53
Average 1M Daily Value	48.59 M GREAT
Average 1W Daily Value	44.59 M GREAT

Timing Factors

28%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

41%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

ポイントになる統計

52%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	2.98 / 449.48
NPM Average (%) / Sector	-27.12 / -1,506.49
NPM Change Average (%) / Sector	-160.77 / 4,940.99
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	2.05 / 30.58
ROA Average (%) / Sector	-10.44 / -347.17
ROA Change Average (%) / Sector	-182.89 / 5,125.52
ROE (%) / Sector	4.32 / -3.58
ROE Average (%) / Sector	-57.59 / 40.65
ROE Change Average (%) / Sector	-200.92 / 2,109.80
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

配当

Dividend (%) / Sector	N/A / 0.05
Dividend Average (%) / Sector	N/A / 16.49
Dividend Change Average (%) / Sector	N/A / 4.17

登録情報

Analyze Date	2026-06-06 09:09:21
Symbol	SRPT
Name	SAREPTA THERAPEUTICS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	105.58 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	1,762.07 / 8,857.28

ニュース

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 215 First Street, Cambridge, MA, United States, 02142

Phone: 617 274 4000

Website: https://www.sarepta.com

Employees: 835

Sector: Healthcare >> Biotechnology

Description: Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.